Fused Bicyclic Compounds for Selective PARP1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PARP inhibitors face challenges in achieving enhanced selectivity for PARP1 while minimizing adverse effects, limiting their efficacy and compatibility with chemotherapeutic drugs.
Innovation Solution
Development of a fused bicyclic compound with specific structural features, including various substituents and heteroatoms, to enhance PARP1 selectivity and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PARP inhibitors are used, then PARP1 inhibition activity is achieved, but selectivity for PARP1 is insufficient and toxicity increases
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at particular positions on the bicyclic core structure. Different substituents (halogens, alkyl groups, heterocyclic groups) are placed at specific locations to optimize interaction with PARP1's binding pocket, enhancing selectivity while controlling toxicity through localized structural modifications rather than global changes
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters including the type of heteroatoms in the bicyclic system, the nature and position of substituent groups, and stereochemical configurations. These parameter variations allow fine-tuning of the compound's affinity for PARP1 versus other PARP family members, thereby improving selectivity and reducing off-target toxicity
2Productivity
If PARP inhibitor dosage is increased to improve efficacy, then therapeutic effect increases, but adverse effects worsen
Solution Approach 1:
The patent uses parameter changes to optimize the therapeutic window by modifying molecular parameters that influence both potency and selectivity. The fused bicyclic structure with tunable substituents allows achievement of high PARP1 inhibition at lower doses, improving efficacy while reducing adverse effects through enhanced target specificity rather than dose escalation
3Adaptability or versatility
If existing PARP inhibitors are combined with chemotherapeutic drugs, then synergistic effect is desired, but compatibility is limited due to toxicity
Solution Approach 1:
The patent applies local quality by designing the bicyclic core with specific functional group placements that enhance PARP1 selectivity. This localized optimization of binding interactions reduces off-target effects and systemic toxicity, thereby improving the safety profile and enabling combination therapy with chemotherapeutic agents that would otherwise be contraindicated due to additive toxicities
Data Source
AI summary
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treating diseases.